Kenvue Inc. (KVUE)

NYSE: KVUE · USD

$19.3

-0.11 (-0.6%)· Recorded snapshot

英語版にフォールバックJA

翻訳中のため英語版を表示しています

このレポートはまだ翻訳されていません。翻訳キューが追いついたら数分後に更新してください。

StockMarketAgent Research · Analyzed 2026-10-04

Our latest published analysis: KVUE rated Hold

Kenvue Inc.'s published Hold conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.

Fair value

$18.2 / share

Potential value

$23.5 / share

Upside to FV

+5.6%

from $19.3

Moat

7.5/10

Narrow

Read full analysis →View archive · 24mo

9-phase methodology · same model in each published edition

Market cap	$33.0B
Revenue (ttm)	15.4B
Net income (ttm)	1.7B
EPS (ttm)	$0.85
Shares out	1.9B
P/E (trailing)	22.7x
P/E (forward)	14.7x
Dividend	$0.84 (4.34%)
Volume	6,839,244
Beta	0.45

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 15.4B
Net income (ttm): 1.7B
EPS (ttm): $0.85
P/E (trailing): 22.7x
P/E (forward): 14.7x
Market cap: $33.0B

Item	P1	P2	P3	P4	P5	Trend
Period	2022-01-02	2023-01-01	2023-12-31	2024-12-29	2025-12-28	Trend
Revenue	$15.05B	$14.95B	$15.44B	$15.46B	$15.12B	+0.1%
Gross profit	$8.42B	$8.29B	$8.64B	$8.96B	$8.79B	+1.1%
Operating income	$2.92B	$2.68B	$2.51B	$1.84B	$2.41B	-4.6%
Net income	$2.08B	$2.06B	$1.66B	$1.03B	$1.47B	-8.3%
EPS (diluted)	$1.21	$1.20	$0.90	$0.54	$0.76	-11.0%
EBITDA	$3.66B	$3.28B	$3.18B	$2.47B	$2.94B	-5.3%
R&D	$355.0M	$375.0M	$399.0M	$408.0M	$382.0M	+1.8%
SG&A	$5.48B	$5.63B	$6.14B	$6.33B	$6.09B	+2.6%

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
ABBV	AbbVie Inc.	505.6B	80.8x	7.9x	17.7%	+3.7%	+29.1%	売り
ABT	Abbott Laboratories	177.6B	38.2x	3.7x	7.2%	+2.7%	-17.2%	縮小
ACN	Accenture plc	144.3B	18.0x	2.0x	27.9%	+8.0%	+0.4%	ホールド
ADM	Archer-Daniels-Midland Company	37.3B	21.2x	0.5x	5.0%	+1.8%	+28.5%	縮小
BF.B	Brown-Forman Corporation Class B	12.7B	17.9x	3.3x	14.3%	+1.6%	+0.4%	買い
CAG	Conagra Brands, Inc.	6.6B	—	0.6x	9.2%	+0.2%	-18.9%	強い買い

Base and Bull scenarios

Base55%

Price target

$18.17

+5.6% from spot

The base outcome assumes steady consumer replenishment in non-discretionary over-the-counter healthcare categories, maintaining predictable top-line progression and stable operating margins. Steady channel execution preserves shelf placement across mass retail partners while cash generation covers regular dividends and scheduled debt maturities. This modal path projects a target of $18.17 with an estimated probability of 55.0%, delivering an implied return of 5.6% against $17.20 (as of 2026-10-02).

Stable revenue growth driven by steady consumer replenishment in essential health categories
Operating margins normalizing gradually with post-separation supply chain efficiencies
Steady retail shelf space allocation with primary distribution partners
Modest capital expenditure supporting disciplined debt service and dividend continuity

Bull20%

Price target

$23.53

+36.8% from spot

In the bull outcome, brand reinvestment and strong clinical positioning accelerate organic revenue expansion across Self Care and international territories. Operating efficiencies expand operating margins toward peer benchmark levels, unlocking superior cash generation. At a target value of $23.53 carrying an estimated probability of 20.0%, this path offers an implied return of 36.8% relative to $17.20 (as of 2026-10-02).

Accelerated organic revenue growth across Self Care and Skin Health
Operating margin expansion toward leading consumer staples peer benchmarks
Enhanced international expansion across emerging markets
Faster debt deleveraging enabling opportunistic share repurchases

Sensitivity: Ke × terminal growth

The highlighted cell is Fair value when every assumption sits at its base level ($18.17). Each row and column shows what Fair value becomes when one assumption moves.

Ke ↓ / g →	1.5%	1.8%	2.0%	2.3%	2.5%
6.2%	$20.0	$20.7	$21.4	$22.2	$23.1
6.7%	$18.5	$19.0	$19.6	$20.3	$21.0
7.2%	$17.3	$17.7	$18.2	$18.7	$19.3
7.7%	$16.2	$16.6	$16.9	$17.4	$17.8
8.2%	$15.3	$15.6	$15.9	$16.2	$16.6

Scorecard

Published factor rows and weighted composite

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/E14.7

P25 10.3P50 14.8P75 20.4

Trailing P/E20.2

P25 12.9P50 18.4P75 30.4

ROE15.6

P25 -19P50 5.1P75 16.5

ROIC12.4

P25 -7P50 6.6P75 13.4

All KVUE indicators

Market & fundamental data

Available fields

264

Groups with data

Currency

USD

Showing 264 of 264 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001944048
Company name	Kenvue Inc.
Country	United States
Country code	US
CUSIP number	49177J102
Earnings date	2026-10-30
Earnings time	bmo
Employees	22,000
Employees change	0
Employees growth	0%
Enterprise value	$44.6B
Exchange	NYSE
Financial currency	USD
Financial report date	2026-06-28
First seen	2026-05-09
Fiscal year end	December
Founded	2022
In index	SP500
Industry	Household & Personal Products
IPO date	2023-05-04
Is primary listing	Yes
Is SPAC	No
ISIN number	US49177J1025
Last 10-K release date	2026-02-20
Last earnings date	2026-08-06
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$37.1B
Market cap category	Large-Cap
Next earnings date	2026-10-30
Options	Yes
Price	$19.32
Price currency	USD
Sector	Consumer Staples
SIC code	2844
Stock price date	2026-10-28
Symbol	KVUE
U.S. state	New Jersey
Website	https://www.kenvue.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Adjusted P/E ratio	16.37x
Average P/E ratio (3Y)	28.87x
Average P/E ratio (5Y)	28.76x
Earnings yield	4.4%
EV/Earnings	27.02x
EV/EBIT	14.87x
EV/EBITDA	12.87x
EV/FCF	23.41x
EV/Sales	2.91x
FCF / EV yield	4.27%
FCF yield	5.13%
Forward EV/Sales	2.84x
Forward P/E	15.98x
Forward P/S	2.36x
Graham number	10.25203
Graham upside	-47.21%
Industry forward P/E	20.32x
Industry P/E	23.22x
Lynch fair value	$4.25
Lynch upside	-78.12%
P/(FCF - SBC) ratio	20.75x
P/(OCF - SBC) ratio	16.89x
P/B ratio	3.54x
P/E ratio	22.72x
P/FCF ratio	19.49x
P/OCF ratio	16.04x
P/S ratio	2.42x
PEG ratio	1.36x
Price/EBITDA ratio	10.72x
Sector forward P/E	21.3x
Sector P/E	28.26x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	19.55%
EBITDA margin	22.59%
Effective tax rate	25.42%
FCF margin	12.42%
Gross margin	58.44%
Operating margin	19.55%
Pretax margin	14.43%
Profit margin	10.76%
Profit per employee	$75,364
Profitable quarters	18
Profitable years	5
Revenue per employee	$700,364
ROA	6.99%
ROA (5Y)	6.28%
ROCE	14.44%
ROE	15.58%
ROE (5Y)	11.18%
ROIC	12.35%
ROIC (5Y)	11.05%
SBC / revenue	0.75%
Tax / revenue	3.67%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth	14.85%
EPS growth (Q)	8.52%
EPS growth (QoQ)	-3.9%
EPS growth 3Y	-7%
EPS growth quarters	6
EPS growth years	1
FCF growth	17.64%
FCF growth (Q)	17.07%
FCF growth (QoQ)	78.29%
FCF growth 3Y	-8.88%
Gross profit growth	2.26%
Gross profit growth (Q)	1.9%
Gross profit growth 3Y	1.64%
Net income growth	16.93%
Net income growth (Q)	8.57%
Net income growth (QoQ)	-3.8%
Net income growth 3Y	-3.52%
Net income growth quarters	6
Net income growth years	1
OCF growth	11.19%
OCF growth (Q)	10.79%
OCF growth (QoQ)	40.7%
OCF growth 3Y	-7.36%
Operating income growth	14.04%
Operating income growth (Q)	1.05%
Operating income growth 3Y	1.91%
Revenue growth	1.76%
Revenue growth (Q)	3.02%
Revenue growth (QoQ)	1.18%
Revenue growth 3Y	-0.02%
Revenue growth quarters	3
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-411M
Depreciation and amortization	$468M
EBIT	$3B
EBITDA	$3.5B
EPS	$0.85
FCF per share	$1.00
Financing cash flow	$-1.9B
Free cash flow	$1.9B
Free cash flow minus SBC	$1.8B
Gross profit	$9B
Income taxes	$565M
Investing cash flow	$-424M
Net borrowing	$-191M
Net cash flow	$40M
Net income	$1.7B
Operating cash flow minus SBC	$2.2B
Operating income	$3B
Revenue	$15.4B
Stock-based compensation	$116M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	2.23
Book value per share	$5.50
Debt / EBITDA	2.44
Debt / equity	0.82
Debt / FCF	4.5
Goodwill	$9.3B
Interest coverage	7.09
Long-term assets	$20.8B
Long-term liabilities	$10.3B
Net cash (debt)	$-7.5B
Net cash / market cap	-20.11%
Net debt / EBITDA	2.16
Net debt / equity	0.71
Net debt / FCF	3.92
Piotroski F-Score	8
Property, plant and equipment	$2.2B
Shareholders' equity	$10.6B
Tangible book value	$-7.1B
Tangible book value per share	$-3.71
Total assets	$26.7B
Total cash	$1.1B
Total debt	$8.6B
Total liabilities	$16.2B
WACC	6.14%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.57
Current assets	$5.9B
Current liabilities	$5.9B
Current ratio	1.01
Inventory turnover	3.66
Net working capital	$369M
Quick ratio	0.61
Working capital	$32M
Working capital turnover	-302.12

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	0.26%
Dividend growth	26.75%
Dividend growth years	2
Dividend payment date	2026-10-02
Dividend payment years	4
Dividend payout frequency	Quarterly
Dividend per share	$0.84
Dividend yield	4.34%
Ex-dividend date	2026-09-21
FCF payout ratio	84.3%
Last dividend	$0.21
Payout ratio	98.82%
Shareholder yield	4.58%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$18.24
1D price change	-0.59%
1M price change	8.48%
1M total return	8.48%
1W price change	0.16%
1W total return	0.16%
1Y price change	28.05%
1Y return CAGR	35.83%
1Y total return	35.8%
20-day SMA	$18.42
200-day SMA	$18.17
3M price change	-0.87%
3M total return	1.43%
3Y price change	6.04%
3Y return CAGR	6.72%
3Y total return	21.54%
50-day SMA	$18.39
50-day SMA vs 200-day SMA	50over200
52-week high	$20.13
52-week high date	2026-07-07
52-week low	$14.02
52-week low date	2025-10-30
6M price change	10.15%
6M total return	14.07%
All-time high	$27.80
All-time high date	2023-05-15
All-time low	$14.02
All-time low date	2025-10-30
Average true range (ATR)	$0.35
Average volume	18.6M
Beta (1Y)	-0.23
Beta (2Y)	0.03
Beta (5Y)	0.45
Change from 52-week high	-4.05%
Change from 52-week low	37.77%
Change from all-time high	-30.53%
Change from all-time low	37.73%
Change from open	0.08%
Day's gap	-0.67%
Dollar volume	$132.1M
High price	$19.47
Low price	$19.25
Monthly RSI	48.63
Open price	$19.30
Position in 52-week range	29.55%
Premarket change	-0.36%
Premarket close	$19.43
Premarket price	$19.36
Previous close	$19.43
Price vs 150-day SMA	5.9%
Price vs 20-day SMA	4.83%
Price vs 200-day SMA	6.29%
Price vs 50-day SMA	5.01%
Relative volume	0.37
Return from IPO open	-23.93%
Return from IPO price	-11.73%
RSI	62.03
Sharpe ratio	1.2
Sharpe ratio (3Y)	0.14
Sortino ratio	2.34
Sortino ratio (3Y)	0.41
Volume	6.8M
Weekly RSI	58
YTD price change	11.94%
YTD total return	17.25%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	1.9B
Float percentage	99.85%
Shares change (QoQ)	0.05%
Shares change (YoY)	-0.26%
Shares held by insiders	0.05%
Shares held by institutions	95.57%
Shares outstanding	1.9B
Short % of float	3.01%
Short % of shares	3%
Short ratio	2.2 days

Deeper analysis on KVUE

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Quote this valuation with its source: Fair value, Potential value and the price at analysis.

Frequently asked questions

About this KVUE report

What is the latest published KVUE stock rating?

Kenvue Inc. is shown with Hold in the latest published report, analyzed 2026-10-04. The hub links directly to the full analysis surface where the dated rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full KVUE analysis?

The full latest published report, analyzed 2026-10-04, lives at /stocks/KVUE/analysis. The bare ticker page summarizes that read and links to each analysis tab; earlier editions remain under /analysis/archive.

What fair value is used for KVUE?

The latest published report analyzed 2026-10-04 gives KVUE a fair value of USD 18 and a potential value of USD 24. These are dated research outputs, not live market prices; review the valuation assumptions, sensitivity analysis, and material risks before making a decision.

How often is the KVUE page updated?

The hub selects the latest published stock report regardless of age and displays its analysis date (2026-10-04). Separately sourced market data is labeled with its own recorded timestamp and is never inferred from the report.

HoldKVUE · Fair value $18.2+5.6%

Read full analysis →

Kenvue Inc. (KVUE)

Our latest published analysis: KVUE rated Hold

Price

Financial snapshot

Fair-value bridge

Latest news · KVUE

Valuation

Profitability

Balance sheet

Trading

Base and Bull scenarios

Sensitivity: Ke × terminal growth

Scorecard

Next earnings

Sector percentile context

All KVUE indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on KVUE

Frequently asked questions

レーティング履歴

Category	Score	Reading
Valuation	6.0
Management	6.5
Balance Sheet	5.0
Profitability	6.5
Revenue Growth	4.5
Risk Assessment	7.5
Competitive Moat	7.5
Earnings Quality	8.0
Capital Efficiency	5.5